Progress in oncology, and more recently ophthalmology, led to the development of VEGF antagonists, three of which are now approved for the treatment of wet AMD. Recent discoveries in ophthalmology ...

Medically reviewed by Andrew Greenberg, MD Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up ...

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.It is often difficult to treat, requires a ...

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

Types of wet AMD treatments. The main treatment involves eye injections of anti-VEGF drugs to stop problematic blood vessel growth. Options include aflibercept, bevacizumab, brolucizumab ...

Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

Australian biotech Opthea (Nasdaq: OPT) is cutting around two-thirds of its workforce, as the company moves to curb spending ...

The success of VEGF antagonists in wet AMD (Table 1) has confirmed the value of targeting angiogenesis in CNV lesions and has led to the development of novel anti-angiogenics, such as dual VEGF ...